(Reuters) -The U.S. Federal Commerce Fee (FTC) has suspended its problem of Amgen (NASDAQ:)’s $27.8 billion buy of Horizon Therapeutics (NASDAQ:), permitting the FTC to think about whether or not the company ought to settle the case, a submitting late on Friday confirmed.

The pause is efficient till Sept. 18.

Amgen stated the corporate was conscious of the transfer and is ready to display that there isn’t any authorized or factual motive to ban the acquisition to the courts.

“We’d be happy if our dedication have been honored as a substitute of going by way of a prolonged courtroom course of,” the corporate stated in a press release including that it anticipates closing the acquisition by mid- December this 12 months.

The FTC filed a lawsuit on Might 16 aimed toward stopping the transaction in a uncommon transfer to dam a big pharmaceutical deal.

The company had stated it opposed the deal due to concern that Amgen would leverage its large promoting medication to strain insurance coverage corporations and pharmacy profit managers to present favorable phrases for Horizon’s two key merchandise – the fast-growing thyroid eye illness remedy Tepezza and gout drug Krystexxa.

The Thousand Oaks, California-based firm introduced plans to purchase Horizon in December final 12 months, saying that its uncommon illness medication would supply it some safety from the drug pricing provisions of the Inflation Discount Act, that are aimed toward medication most generally utilized by the federal government’s Medicare well being plan.

The company and Amgen are resulting from meet over the injunction in Chicago federal courtroom in September.

Horizon Therapeutics didn’t instantly reply to a Reuters’ request for remark.